Fig. 5From: The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AMLThe comparison of risk scores in different ELN2017 risk groups (A), with or without MDS history (B), de novo or relapsed AML (C). **p value < 0.01; *p value < 0.05Back to article page